Page last updated: 2024-08-24

nelfinavir and Abnormalities, Drug-Induced

nelfinavir has been researched along with Abnormalities, Drug-Induced in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gocke, E; Müller, L; Pfister, T	1
Bürgin, H; Gocke, E; Müller, L; Pfister, T	1
Conner, SD; Covington, DL; Daniels, EM; Doi, PA; Swinson, J	1
Beckerman, K; Chavers, S; Covington, DL; Dominguez, K; Garcia, P; Ross, B; Sacks, S; Scheuerle, A; Tilson, H; Watts, DH	1

Reviews

1 review(s) available for nelfinavir and Abnormalities, Drug-Induced

Article	Year
Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; DNA; DNA Damage; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; HIV Protease Inhibitors; Humans; Male; Mice; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests	2009

Article

Year

Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.

Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3

Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; DNA; DNA Damage; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; HIV Protease Inhibitors; Humans; Male; Mice; Nelfinavir; Neoplasms; No-Observed-Adverse-Effect Level; Rats; Reproduction; Risk Assessment; Toxicity Tests

2009

Other Studies

4 other study(ies) available for nelfinavir and Abnormalities, Drug-Induced

Article	Year
EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations. Toxicology letters, 2009, Nov-12, Volume: 190, Issue:3 Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; Carcinogenicity Tests; Dose-Response Relationship, Drug; Drug Contamination; Ethyl Methanesulfonate; Female; Genes, Dominant; Genes, Lethal; Germ-Line Mutation; HIV Protease Inhibitors; Humans; Linear Models; Mammary Neoplasms, Animal; Methyl Methanesulfonate; Mice; Mutagenicity Tests; Nelfinavir; No-Observed-Adverse-Effect Level; Pregnancy; Quantitative Structure-Activity Relationship; Rats; Risk Assessment	2009
Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstetrics and gynecology, 2004, Volume: 103, Issue:6 Topics: Abnormalities, Drug-Induced; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Prospective Studies; Registries; Risk	2004
[HAART and pregnancy. Nelfinavir superiority in hepatotoxicity]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Abnormalities, Drug-Induced; Animals; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Risk Assessment	2004
Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. American journal of obstetrics and gynecology, 2004, Volume: 191, Issue:3 Topics: Abnormalities, Drug-Induced; Anti-Retroviral Agents; Female; Gestational Age; Humans; Lamivudine; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Prospective Studies; Risk Factors; Stavudine; Zidovudine	2004